A Phase 3 interventional study of tadalafil and tadalafil in Pulmonary Hypertension, sponsored by Eli Lilly and Company. Completed at 6 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2008-02-21.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tadalafil in Hypertension, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Tadalafil · Hypertension, Pulmonary.
Among the 18 studies testing tadalafil in Hypertension, Pulmonary, this one is the 2nd largest by enrollment, is one of 2 that started in 2005, is one of 8 in phase 3, and was the 1st registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →3 of the 18 studies testing tadalafil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 35–89
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 40 across the 18 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
2 of the studies testing tadalafil in Hypertension, Pulmonary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing tadalafil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension.
This is a randomized, double-blind, placebo-controlled, multicenter study. The key measure of effectiveness of the study drug will be determined using a 6-minute walk test. Eligible patients will be treated for 16 weeks and may be eligible to enter a 52-week extension phase study (PHIRST-2). Study procedures for both studies (PHIRST-1 and PHIRST-2) will include routine blood tests, medical history, physical exams, questionnaire responses, and exercise tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: placebo
2.5 mg tadalafil
Drug: tadalafil
10 mg tadalafil
Drug: tadalafil
20 mg tadalafil
Drug: tadalafil
40 mg tadalafil
Drug: tadalafil
tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
Also known as: LY450190, Cialis, IC351
tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
Also known as: LY450190, Cialis, IC351
tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
Also known as: LY450190, Cialis, IC351
tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
Also known as: LY450190, Cialis, IC351
placebo tablet taken by mouth once a day for 16 weeks
6 minute walk distance change from baseline to Week 16
Time frame: 16 weeks
World Health Organization (WHO) functional class, Borg dyspnea, cardiopulmonary hemodynamics, quality of life - change from baseline to Week 16
Time frame: 16 weeks
Time to first occurrence of clinical worsening
Time frame: Not defined
The record gives a start of Aug 2005, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil